Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Tessellate BIO has raised $8.5M in total funding. The most recent round was Seed. The last funding was announced in October 2023.
Tessellate BIO's investors include Forbion Capital Partners, BioGeneration Ventures.
Tessellate BIO is headquartered in Naarden, The Netherlands.
Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Tessellate BIO is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tessellate BIO — Funding & Investors." VCBacked, October 17, 2023, https://www.vcbacked.co/company/tessellate-bio. Accessed August 15, 2026.
VCBacked. (2023). Tessellate BIO — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/tessellate-bio
{{cite web |title=Tessellate BIO — Funding & Investors |url=https://www.vcbacked.co/company/tessellate-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated